Prognosis and Treatment of Myositis‐Associated Severe Interstitial Lung Disease: A Descriptive Study Using a Nationwide Inpatient Database in Japan
- 10 May 2021
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 74 (3) , 478-483
Abstract
Objective: The aim of this study was to determine the prognosis, clinical course, and current management of severe interstitial lung disease (ILD) associated with myositis in Japan.Methods: We conducted a retrospective descriptive study using a nationwide database for inpatient care of acute illness in Japan. Among a total of ~66 million inpatient admissions, we identified patients with severe ILD associated with polymyositis (PM) or dermatomyositis (DM) who required mechanical ventilation and methylprednisolone pulse therapy (≥1 gm/day of methylprednisolone) from July 2010 to March 2018.Results: We identified 155 patients with PM and 394 with DM who fulfilled the above criteria. The median age of patients was 65 years; DM patients were significantly younger than PM patients (64 versus 68 years; P < 0.001). The numbers of patients who were treated with calcineurin inhibitors, intravenous cyclophosphamide, and polymyxin B–immobilized fiber column direct hemoperfusion (PMX‐DHP) were 403 (73.4%), 318 (57.9%), and 78 (14.2%), respectively. All these treatments were given significantly more frequently to the patients with DM compared with those with PM. The uses of other treatment options were much less frequent. The median periods after hospitalization when methylprednisolone pulse therapy, calcineurin inhibitors, mechanical ventilation, intravenous cyclophosphamide, and PMX‐DHP were initiated and in‐hospital death occurred among patients with DM were 2, 4, 7, 8, 17, and 36 days, respectively. In‐hospital mortality was significantly higher in patients with DM than in those with PM (76.6% versus 56.8%; P < 0.001).Conclusion: The mortality of patients with myositis‐associated severe ILD who require mechanical ventilation is extremely high despite aggressive and prompt interventions.Keywords
Funding Information
- Ministry of Health, Labour and Welfare, Japan (19AA2007, 20AA2005)
This publication has 14 references indexed in Scilit:
- Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive DermatomyositisJCR: Journal of Clinical Rheumatology, 2019
- Effect of cyclosporine A on mortality after acute exacerbation of idiopathic pulmonary fibrosisJournal of Thoracic Disease, 2018
- Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patientsRheumatology, 2018
- Validity of diagnoses, procedures, and laboratory data in Japanese administrative dataJournal of Epidemiology, 2017
- Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort studySpringerPlus, 2015
- Favorable outcome with hemoperfusion of polymyxin B-immobilized fiber column for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of three casesModern Rheumatology, 2014
- Prevalence and incidence of polymyositis and dermatomyositis in JapanModern Rheumatology, 2013
- Polymyxin B-immobilized Fiber Column (PMX) Treatment for Idiopathic Pulmonary Fibrosis with Acute Exacerbation: A Multicenter Retrospective AnalysisInternal Medicine, 2012
- Short‐term and long‐term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patientsArthritis & Rheumatism, 2011
- Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort studyClinical Rheumatology, 2007